Medicine · 2025
Fatal interstitial lung disease associated with rituximab in diffuse large B-cell lymphoma: A case report and literature review.
СтатьяКлинический случайОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Li, Liu Fei, Zhou Jie, Chen Xiang-Lei
Аннотация
RATIONALE: Rituximab-associated interstitial lung disease (ILD) may initially be asymptomatic, and serial monitoring of serum tumor necrosis factor-alpha levels may facilitate timely diagnostic intervention with pulmonary computed tomography.
PATIENT CONCERNS: A 73-year-old patient with diffuse large B-cell lymphoma (DLBCL) developed ILD during treatment with a rituximab-containing regimen.
DIAGNOSES: Rituximab-associated interstitial disease was made.
INTERVENTIONS: The patient was treated with corticosteroids, intravenous immunoglobulin, and antifibrotic therapy.
OUTCOMES: The ILD progressed, and the patient ultimately succumbed to type I respiratory failure.
LESSONS: Clinicians should remain vigilant for rituximab-associated ILD, which, although uncommon, can progress rapidly and result in poor outcomes.
PATIENT CONCERNS: A 73-year-old patient with diffuse large B-cell lymphoma (DLBCL) developed ILD during treatment with a rituximab-containing regimen.
DIAGNOSES: Rituximab-associated interstitial disease was made.
INTERVENTIONS: The patient was treated with corticosteroids, intravenous immunoglobulin, and antifibrotic therapy.
OUTCOMES: The ILD progressed, and the patient ultimately succumbed to type I respiratory failure.
LESSONS: Clinicians should remain vigilant for rituximab-associated ILD, which, although uncommon, can progress rapidly and result in poor outcomes.